patients who presented with mutant DNA methyltransferase 3 alpha (DNMT3A) at diagnosis. This led them to assume that mutations in DNMT3A may cause genetic instability and thereby induce FLT3-ITD, ultimately leading to relapse of AML.
Natural history of acute lymphoblastic leukemia in neurofibromatosis type 1 monozygotic twins Leukemia (2013) 27, 1778-1781; doi:10.1038/leu.2013.55
Although the natural history of acute lymphoblastic leukemia (ALL) is clinically silent, identical twin pairs suffering from concordant leukemia provide a unique and tractable model to better understand the clonal evolution of this disease. 1 Recently, genetic studies on ALL have revealed not a linear sequence of mutation acquisition but rather a clonal development model based on complex branching similar to Darwin's evolution trees and natural selection. Indeed, a frequently occurring prenatal first hit is followed by the acquisition of critical and secondary copy number alterations (CNAs) in different subclones, which gain a selective advantage giving rise to leukemia.
Neurofibromatosis type 1 (NF1). Both patients were diagnosed with concordant ALL, aged 6 and 6.5 years. Genome-wide array analysis of these identical twins led us to hypothesize that they might represent a bona fide model of leukemia clonal evolution associated to NF1. NF1 is an autosomal dominant disorder caused by mutations of the NF1 gene, located at chromosome band 17q11.2, encoding for neurofibromin, a GTPase-activating protein that negatively regulates the activation of Ras family members. Clinical features of NF1 include alterations of skin pigmentation (cafè-au-lait macules), benign neurofibromas 3 and predispositions to malignancies, 4 mainly myeloid leukemia. 5, 6 Monoallelic loss of NF1 followed by its bi-allelic inactivation through a second hit has a role in neoplastic progression of somatic cells. 7, 8 Nevertheless, the sequence of events occurring during clonal evolution from NF1 mutations to the development of leukemia still remains poorly understood.
T1 and T2 were diagnosed with NF1 in the first year of life. They showed NF1 clinical features and sequencing data confirmed the presence of an identical inactivating germline NF1 mutation (2763insA) in both the children (data not shown). The clinical, immunophenotypic and cytogenetic data of T1 and T2 at diagnosis and relapse are summarized in Supplementary  Table 1 . At diagnosis, T1 bone marrow (BM) aspirate analysis confirmed diagnosis with common B-cell precursor ALL with karyotype 45,XX,-7,del(9)(p12),del(10)(q23) [8] /46,XX [12] ; peripheral blood analysis performed on T2 at that time was normal. Five months after T1 onset, T2 was diagnosed with common ALL with 100% BM blasts infiltration, karyotype 45,XX, À 7,del(10)(q22) [14] .
Immunoglobulin/T-cell receptor (Ig/TcR) monoclonal rearrangements found at diagnosis (T1 and T2) and relapse (only T2) were used to quantify the minimal residual disease (MRD) at three follow-up time points (day þ 15, day þ 33 and day þ 78) according to the AIEOP-BFM ALL2000 protocol. 9 Twins were stratified according to the criteria described by Conter et al. 10 : T1 was classified as MRD high risk (HR), while T2 was MRD intermediate (IR) risk. T1 was subjected to BM transplantation 8 months after diagnosis and remained in clinical remission at 90 months, while T2 relapsed after 13 months from diagnosis as common ALL and karyotype 47,XX,del(9) (p21), þ 21 [11] /46,XX [5] .
At diagnosis, T1 and T2 showed completely different Ig/TCR rearrangements as shown in Supplementary Table 2. Highly sensitive (X1.0 Â 10 À 4 ) cross analysis of diagnostic markers in both the twins did not show any common rearrangements (Supplementary Table 3 ). Three clonal rearrangements were also found in the T2 relapse sample (Supplementary Table 2 ) not related to the T2 diagnostic ones.
By rearrangement backtracking, we detected both T2 relapse clonal rearrangements in the diagnostic sample of T2 but not T1. They accounted for a clone corresponding to about 1% of cells (1.8 Â 10 À 2 and 8 Â 10 Table 3) .
The genome-wide CNA analysis (see Supplementary table 4) indicated that T1 and T2 at diagnosis and T2 at relapse shared only one common aberration, namely the copy number neutral loss of heterozygosity (LOH) of the whole long arm of chromosome 17, where the NF1 gene is located ( Figure 1A) . Both diagnostic samples of the twins (but not the T2 relapse sample) showed chromosome 7 monosomy; we did not ascertain the parental origin of this chromosome. Nine additional chromosomal abnormalities were found to be specific for each twin, five for T1 and four for T2 ( Figure 1A and Supplementary Figure 2) .
The T2 relapse clone showed the same LOH 17q and del(15)(q21.3) found in its diagnostic sample, and as expected, several adjunctive CNAs as heterozygous deletions affecting single genes (IKZF1, ETV6, C20orf94) (Supplementary Figure 1B) , trisomy 21 and a complex rearrangement of chromosome 20 (Supplementary Figure 2 ). Deletions associated with TCR clonal rearrangements at diagnosis and relapse, visible and distinct for both twins, are listed in Supplementary Table 5 .
The role of NF1 mutations during clonal evolution of ALL is still not completely understood. We report, for the first time, the occurrence of LOH as a prenatal lesion predisposing to leukemia in a pair of twins suffering from NF1. Furthermore, we have characterized the succession of events leading to leukemia from the prenatal phase in one of these NF1 twins.
Indeed, the combination of genome-wide copy number analysis and Ig/Tcr rearrangements monitoring has led us to hypothesize a model of clonal evolution of leukemia in NF1 twins (Figure 2 ).
The uniqueness of 17q LOH as a common feature between twins and its persistency from diagnosis to relapse in T2 suggests that 17q LOH is most probably a single cell or a clonal event occurring prenatally in one twin. This conclusion is also supported by previous data showing shared and identical gene fusions in other monozygotic twin pairs with concordant ALL; 1 it is likely that blood cell chimeras might have facilitated the spread of clonal leukemia or progeny from one twin to the other due to their monochorionic status in the uterus. 1 The identification of the same NF1 mutation (2763insA) in T1 and T2 confirmed it to be a primary event linked to the disease that preceded LOH. Moreover, IgH and TCR rearrangements were clonally distinct. We cannot, therefore, rule out that both twins were at a greater risk of leukemia because of their constitutive NF1 status; in this scenario, selective pressure due to the loss of the normal NF1 allele resulted in both of them losing the entire long arm of chromosome 17, but independently and along with uniparental disomy of the 17q carrying the constitutive NF1 mutation. If that were to be the case, the 17q-could have arisen either pre-or postnatally. We note that NF1-associated ALL (rather than CMML or AML) is extremely rare. 6, 11 It is therefore unlikely that these twins developed ALL independently.
After birth, each clone had an independent evolution, as shown by specific Ig/TCR rearrangements and the accumulation of different lesions. These findings further suggest that 17q LOH occurred very early during differentiation, before somatic recombination. The monosomy 7 (frequently described in myeloid disorders and rarely associated with lymphoid malignancies) 11, 12 should have occurred as an independent and postnatal acquisition, as sustained by the loss of this aberration at T2 relapse.
Few additional aberrations were then required for the progression to full leukemia in both the twins. Interestingly, we found new lesions herewith reported for the first time as deleted in leukemia, in particular, a 292-kb deletion on chromosome 6 involving the BACH2 gene and a focal deletion of 130 kb on chromosome 15 involving the TCF12 gene. BACH2 is a human B-cell specific transcriptional repressor; it is involved in B-cell differentiation and has been described as a tumor suppressor gene; 13 TCF12 (also named HEB) is a member of the basic helix-loop-helix E-protein family and is involved in B-and T-cell commitment.
14 The altered expression of these genes could contribute to the differentiation arrest and the uncontrolled proliferation of leukemic blasts. However, an in-depth study of these lesions might reveal new leukemia pathogenetic mechanisms.
Backtracking of Ig/TCR and CNA analysis of the T2 relapse sample strongly suggests that the relapse might have originated from an intermediate stage preceding the first leukemia presentation in T2 (Figure 2 ). This stage was formed by a clonal cell population representing about 1% of leukemia at first presentation derived from a post-natal pre-leukemic clone with a TCF12 deletion. This cell population underwent further clonal evolution through the acquisition of additional chromosomal aberrations involving known lesions, such as ETV6 and Ikaros deletions, the last one recently described as negative prognostic factor in pediatric BCP-ALL patients. 15 In addition, it is likely that other genes located in regions of CNA might have contributed to the progression to full leukemia.
In conclusion, the in-depth analysis of clonal and tumorigenic events in a twin pair has let us establish a chronological series of transforming events that allows a pre-natal pre-leukemic clone in a patient with a predisposing disease to become fully leukemic and, subsequently, to acquire additional lesions that could favor the relapse of the disease.
